The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 30, 2017
Filed:
Jan. 16, 2014
Applicant:
Bristol-myers Squibb Company, Princeton, NJ (US);
Inventors:
Ryan M. Moslin, Princeton, NJ (US);
David S. Weinstein, East Windsor, NJ (US);
Stephen T. Wrobleski, Flemington, NJ (US);
Yanlei Zhang, Princeton Junction, NJ (US);
John S. Tokarski, Princeton, NJ (US);
Michael E. Mertzman, New Hope, PA (US);
Chunjian Liu, Pennington, NJ (US);
Assignee:
Bristol-Myers Squibb Company, Princeton, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 213/56 (2006.01); C07D 405/12 (2006.01); C07D 401/12 (2006.01); C07D 213/82 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07B 59/00 (2006.01);
U.S. Cl.
CPC ...
C07D 213/82 (2013.01); C07B 59/002 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07B 2200/05 (2013.01); C07D 213/56 (2013.01);
Abstract
Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.